S

SCYNEXIS
D

SCYX

1.22000
USD
0.03
(2.52%)
Market Closed
Volume
828
EPS
-0
Div Yield
-
P/E
-2
Market Cap
46,290,754
OverviewSignalsIdeasNews
Related Instruments
    A
    ADVM
    -0.40000
    (-5.51%)
    6.86000 USD
    A
    AEMD
    0.00400
    (1.04%)
    0.39000 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    B
    BTAI
    0.05300
    (10.50%)
    0.55800 USD
    E
    EIGR
    0
    (0%)
    0.000000 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    R
    RIGL
    -3.530
    (-12.78%)
    24.100 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    More
News

Title: SCYNEXIS

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.